Published in Nature on April 16, 1981
Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol (1988) 3.84
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Multiple viral mutations rather than host factors cause defective measles virus gene expression in a subacute sclerosing panencephalitis cell line. J Virol (1988) 1.84
Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. J Exp Med (1989) 1.41
Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J Virol (1990) 1.36
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Prospective immunological assessment of arthritis induced by rubella vaccine. Infect Immun (1983) 1.17
Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Med Microbiol Immunol (2010) 1.13
Measles virus, immune control, and persistence. FEMS Microbiol Rev (2012) 1.12
Reversible repression and activation of measles virus infection in neural cells. Proc Natl Acad Sci U S A (1982) 1.04
Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. J Virol (1987) 1.01
Isolation of cold-sensitive mutants of measles virus from persistently infected murine neuroblastoma cells. J Virol (1984) 0.99
Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells. J Virol (1992) 0.97
Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol (1986) 0.96
Productive measles virus brain infection and apoptosis in CD46 transgenic mice. J Virol (2000) 0.87
Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology (1986) 0.87
Antibodies to varicella-zoster virus modulate antigen distribution but fail to induce viral persistence in vitro. J Virol (1992) 0.77
Tyrosine phosphorylation of measles virus nucleocapsid protein in persistently infected neuroblastoma cells. J Virol (1995) 0.77
In vitro modulation of viral cell surface glycoproteins by anti-viral antibody in the presence of complement. Clin Exp Immunol (1982) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3.65
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. J Infect Dis (1972) 2.56
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med (1986) 2.22
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol (1989) 2.11
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann N Y Acad Sci (1966) 2.02
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain (1998) 1.96
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature (1993) 1.89
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest (1981) 1.84
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci (1995) 1.82
The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol (1991) 1.81
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest (2001) 1.74
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. AJNR Am J Neuroradiol (2009) 1.66
Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J Immunol (1977) 1.58
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol (1993) 1.58
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol (1994) 1.52
Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol (1985) 1.52
Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol (1969) 1.51
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol (1989) 1.46
In vitro studies of cell-mediated immunity in an acute viral infection. J Immunol (1974) 1.46
Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol (2001) 1.45
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.45
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol (1992) 1.43
Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci U S A (1994) 1.41
Immunoglobulin A production in ataxia telangiectasia. Science (1965) 1.41
The effect of measles virus infection on T and B lymphocytes in the mouse. I. Suppression of helper cell activity. J Immunol (1974) 1.40
Serial MR imaging of experimental autoimmune encephalomyelitis induced by human white matter or by chimeric myelin-basic and proteolipid protein in the common marmoset. AJNR Am J Neuroradiol (1999) 1.40
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol (1992) 1.40
Specificity of the inflammatory response in viral encephalitis. I. Adoptive immunization of immunosuppressed mice infected with Sindbis virus. J Exp Med (1972) 1.39
An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med (1970) 1.38
Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest (1968) 1.38
Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (1987) 1.36
Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J Immunol (1983) 1.35
The germline repertoire of T cell receptor beta-chain genes in patients with chronic progressive multiple sclerosis. J Neuroimmunol (1989) 1.32
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
Contact sensitivity in the pig. Immunology (1973) 1.30
Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol (2007) 1.30
The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol (1995) 1.27
Immunological studies in tropical spastic paraparesis. Ann Neurol (1990) 1.26
Recurrent experimental allergic encephalomyelitis in the Lewis rat. J Immunol (1974) 1.26
Cell type-specific regulation of major histocompatibility complex (MHC) class I gene expression in astrocytes, oligodendrocytes, and neurons. Glia (1993) 1.25
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler (1995) 1.24
Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab Invest (1980) 1.24
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain (2003) 1.22
Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Science (1973) 1.21
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol (1993) 1.20
Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J Immunol (1983) 1.20
Lymph node function and lymphocyte circulation in the pig. Adv Exp Med Biol (1973) 1.20
Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol (2001) 1.20
Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis (2000) 1.19
Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol (1990) 1.18
Thymic epithelial cell contains acetylcholine receptor. Lancet (1977) 1.18
Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. J Autoimmun (2001) 1.18
Multiple sclerosis (second of two parts). N Engl J Med (1982) 1.18
Measles virus persistence in human lymphocytes: a role for virus-induced interferon. J Gen Virol (1982) 1.17
Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest (1984) 1.17
Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann Neurol (1999) 1.17
Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol (1998) 1.16
In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. AJNR Am J Neuroradiol (2006) 1.16
Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep (2001) 1.16
Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol (1993) 1.15
Immune response of Lewis rats to peptide C1 (residues 68-88) of guinea pig and rat myelin basic proteins. J Exp Med (1977) 1.15
T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity (1993) 1.15
MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology (2005) 1.14
Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol (1988) 1.14
Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease. N Engl J Med (1997) 1.13
Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology (1995) 1.12
Presentation of myelin basic protein by murine cerebral vascular endothelial cells. J Immunol (1985) 1.11